Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation